|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Thirteen patients had invasive ductal carcinoma: 8 (61.5%) were hormone receptor-positive; 6 (46.1%), human epithelial growth factor receptor 2 (HER2)-amplified.
|
31748977 |
2020 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
MBC is more often triple negative (ER-, PR-, HER2-) and is associated with poorer clinical outcome when compared with infiltrating ductal carcinoma.
|
30537493 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
To the best of our knowledge, recurrence of invasive ductal carcinoma in the form of metaplastic squamous cell carcinoma of basal-HER2 subtype has not been reported previously.
|
31598347 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We present a case of a woman on neratinib for HER-2 positive infiltrating ductal carcinoma of the right breast who presented to the dermatology clinic with changes to the fingernails, acne, and a rash on the face.
|
30321080 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The main pathological parameters such as estrogen receptor (ER), progesterone receptor (PR), and human epithelial growth factor receptor 2 (C-erbB-2) were detected by immunohistochemistry (IHC), and the clinicopathologic and prognostic difference were compared with invasive ductal carcinoma (IDC).
|
31119054 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In all, 134 patients with ER+/HER2- invasive ductal carcinoma who underwent both breast MRI and Oncotype Dx RS evaluation.
|
30129697 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The preoperative histopathological diagnosis of the right-sided breast tumor was invasive ductal carcinoma, T2N0M0 stage IIA, with negative results for hormone receptors and human epidermal growth factor receptor 2.
|
30854057 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Core biopsy revealed that she had grade II oestrogen receptor-negative, Her2-positive invasive ductal carcinoma.
|
30423570 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This pooled retrospective analysis of three clinical studies demonstrates that the magnitude of benefit of eribulin in the metastatic setting did not differ between patients with ILC versus invasive ductal carcinoma (IDC), even when restricting for patients with estrogen receptor-positive/HER2-negative IDC.
|
30578311 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of human epidermal growth factor receptor 2 (HER2) protein is well known to be more frequent in ductal carcinoma in situ (DCIS) than in invasive ductal carcinoma (IDC).
|
31192864 |
2019 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
SUVmax and SUVmean were higher for triple-negative and HER2+ IDBC than for ER+/HER2- IDBC.
|
29135722 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Two cohorts were assessed: (1) 60 FFPE infiltrating ductal carcinoma (IDCA) cases and (2) 20 FFPE IDCA cases with ductal carcinoma in situ (DCIS) with a range of HER2 expression as determined by clinical immunohistochemistry and fluorescence in situ hybridization (IHC/FISH).
|
29858579 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
An advanced HER-2-enriched invasive ductal carcinoma was diagnosed.
|
30558095 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The molecular subtype was an independent prognostic factor for early invasive ductal carcinoma (odds ratios for luminal B, Basal-like, and Her-2 overexpression were 2.900, 5.232 and 4.214, respectively; all P<0.05).
|
29599829 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The investigated group consisted of 117 patients with invasive ductal breast cancer (T≥1, N≥0, M0) with overexpression of HER2, who underwent radical surgery between 2007 and 2014.
|
30122944 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We compared biological and clinical characteristics of HER2-positive ILC versus HER2-positive infiltrating ductal carcinoma (IDC).
|
29759595 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Tissue microarray data from 84 patients with various stages of mammary carcinoma, including (in order of increasing malignant potential) normal, usual hyperplasia, fibrocystic changes, fibroadenoma, carcinoma-in-situ, and invasive ductal carcinoma showed a statistically significant association between Smurf2 and CNKSR2 expression, which is also well correlated with the ER, PR, and HER2 status of the tissue samples.
|
29534682 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
To the authors' knowledge, this is the first report indicating that women with human epidermal growth receptor 2 (HER2) positive metaplastic breast cancer have survival superior to women with HER2 negative metaplastic breast cancer and survival similar to women with HER2 positive invasive ductal carcinoma.
|
29330212 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
The expression of S100A8 and ASAH1, as well as ER, PR, HER2 and Ki-67 were assessed by immunohistochemical staining in 120 cases of non-special type invasive ductal carcinoma (IDC-NOS).
|
29320752 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Association among T2 signal intensity, necrosis, ADC and Ki-67 in estrogen receptor-positive and HER2-negative invasive ductal carcinoma.
|
30172938 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Invasive ductal carcinoma (IDC) is subtyped according to estrogen-receptor (ER), progesterone-receptor (PR), and HER2 status, among other markers.
|
30170496 |
2018 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We assessed the role of Ki67, hormone receptors expression, HER2, MYC genes and their protein status, and KRAS codon 12 mutations as predictor factors of pathologic response to anthracycline-cyclophosphamide (AC) followed by taxane docetaxel (T) neoadjuvant chemotherapy (AC+T regimen) in 51 patients with invasive ductal breast cancer.
|
28089283 |
2017 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study shows that BI-RADS 3-5 microcalcifications can be conveniently used to facilitate the preoperative prediction of HER2 and Luminal A molecular subtype in patients with infiltrating ductal carcinoma.
|
28099938 |
2017 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
CTD_human |
The scaffolding protein NHERF1 regulates the stability and activity of the tyrosine kinase HER2.
|
28235801 |
2017 |
|
Invasive Ductal Breast Carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We investigated statistically derived indicators of HER2 heterogeneity in HER2 FISH data obtained by automated IA of 50 IHC borderline (2+) cases of invasive ductal breast carcinoma.
|
28752092 |
2017 |